Aclaris Therapeutics ACRS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.78M (1 inflow days, 19 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 32.9% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 9.99% to 7.47% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +6,733,978 | 4.4% |
| Artal Group S.A. | VC/PE Fund | 2026/Q3 | +2,025,000 | 1.3% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +871,027 | 0.5% |
| Putnam LLC | Mutual Fund | 2026/Q3 | +870,952 | 0.5% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +574,584 | 0.5% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +440,804 | 2.3% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +395,736 | 2.3% |
| Barclays PLC | Public Company | 2026/Q3 | +381,828 | 0.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +339,584 | 6.5% |
| Harvest Investment Services, LLC | Mutual Fund | 2026/Q3 | +292,598 | 0.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +227,500 | 0.3% |
| Frazier Life Sciences Management, LP | VC/PE Fund | 2026/Q3 | +3,804,142 | 5.5% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +249,775 | 0.2% |
| RA Capital Management, L.P. | VC/PE Fund | 2026/Q3 | +5,918,954 | 8.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +2,629,943 | 6.8% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 31 Jul 2026 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Sale | -12,385 | $5.20 | 23,990 |
| 31 Jul 2026 | Roland Kolbeck | Chief Scientific Officer | Derivative Exercise and Retained | +23,990 | – | 23,990 |
| 4 Jun 2026 | Vincent Milano | Independent Director | Derivative Exercise and Retained | +11,580 | – | 28,896 |
| 4 Jun 2026 | Andrew Schiff | Independent Director | Derivative Exercise and Retained | +11,580 | – | 25,540 |
| 4 Jun 2026 | Maxine Gowen | Independent Director | Derivative Exercise and Retained | +11,580 | – | 33,334 |
| 4 Jun 2026 | William Humphries | Independent Director | Derivative Exercise and Retained | +11,580 | – | 45,105 |
| 4 Jun 2026 | Anand Mehra | Independent Director | Derivative Exercise and Retained | +11,580 | – | 726,403 |
| 4 Jun 2026 | Christopher Molineaux | Lead Independent Director | Derivative Exercise and Retained | +11,580 | – | 69,536 |
| 3 Jun 2026 | Vincent Milano | Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | Vincent Milano | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
| 3 Jun 2026 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | Andrew Schiff | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
| 3 Jun 2026 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | Maxine Gowen | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
| 3 Jun 2026 | William Humphries | Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | William Humphries | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
| 3 Jun 2026 | Anand Mehra | Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | Anand Mehra | Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
| 3 Jun 2026 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +10,987 | – | 10,987 |
| 3 Jun 2026 | Christopher Molineaux | Lead Independent Director | Other Derivative Acquisition | +42,350 | $4.71 | 42,350 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 11,572,867 | 7.5% | 4.0 |
| 15 Oct 2026 | 15,027,284 | 10.2% | 3.0 |
| 30 Sep 2026 | 18,191,280 | 12.4% | 6.5 |
| 15 Sep 2026 | 16,075,295 | 10.9% | 6.4 |
| 31 Aug 2026 | 15,180,778 | 10.3% | 8.7 |
| 14 Aug 2026 | 14,710,712 | 10.0% | 7.0 |
No comments yet — be the first to weigh in on ACRS.
Sign in to join the discussion.